StemCell Therapy

By: New York Times | Published: April 2, 2020 10:59:26 pm On Saturday, the FDA took the unusual step of approving those drugs to treat hospitalized patients with coronavirus on an emergency basis, even though no significant clinical trials have yet been done.

Written by Katie Thomas

An experimental stem cell therapy derived from human placentas will begin early testing in patients with the coronavirus, a New Jersey biotech company said Thursday.

The treatment, being developed by the company Celularity, has not yet been used on any patients with symptoms of COVID-19, but it has caught the attention of Rudy Giuliani, President Donald Trumps personal lawyer. Giuliani recently featured an interview with the company founder on his website and said on Twitter that the product has real potential, while also criticizing the Food and Drug Administration for not moving more quickly to approve potential remedies.

There is no proven treatment for the respiratory disease, but several experimental approaches, including old malaria drugs and HIV antivirals, are being tested in patients around the world.

READ | Video from Japan shows how COVID-19 is getting transmitted through a third route

Celularity has also enthusiastically publicized the news of its early-stage trial for its treatment, known as CYNK-001. In an email Wednesday to a reporter, its public relations firm described a development as the first FDA approval for COVID-19 cell therapy. The agencys decision, however, merely gives a green light for its product to be used in a clinical trial, not widely prescribed to patients.

In recent weeks, the established scientific process of evaluating a drugs safety and effectiveness has been upended by Trump, who has repeatedly promoted the potential of two long-used malaria drugs that have shown mainly anecdotal evidence of helping patients. On Saturday, the FDA took the unusual step of approving those drugs to treat hospitalized patients with coronavirus on an emergency basis, even though no significant clinical trials have yet been done.

The early trial by Celularity which will primarily evaluate safety, as well as an initial look at efficacy will test its therapy in up to 86 patients with symptoms. They will receive infusions of the cell therapy in the hopes it will prevent them from developing the more severe form of the disease, Dr. Robert Hariri, Celularitys founder and chief executive, said in an interview Wednesday.

The objective here is preventative, Hariri said. If the timing of giving this can prevent those patients who have early disease from progressing to the more serious, life-threatening form, it could be a very, very useful tool.

The therapy involves using stem cells from the placenta known as natural killer cells that help protect a developing fetus or newborn from viruses that have infected the mother. Celularity has been testing these cells in cancer patients.

Hariri said the trial, which would not include a placebo control group, will take place at academic medical centers around the country. He said the company expected to see initial results about 30-60 days after the first patients receive their dose. If this study is successful, Hariri said, the company would move to a placebo-controlled study that would evaluate the drugs efficacy against the disease.

At least one outside expert said the approach could present safety risks. Paul Knoepfler, a stem cell researcher at the University of California, Davis, said that patients with coronavirus can develop severe reactions where their immune systems go too far in attacking cells in their lungs, causing damaging inflammation. Other cell therapies tested in China are designed to dampen the immune response. He said one risk with the natural killer cells is they could go in the other direction, exacerbating respiratory problems by massive killing of the patients respiratory cells.

Despite the scant evidence, Giuliani has become an early booster, interviewing Hariri on a podcast published on his website Saturday and praising the treatment on Twitter, saying, this therapy has real potential. In a tweet Saturday, he added, Lets hope FDA can recognize that their cumbersome process designed to keep us safer, if it is not altered dramatically in times of great need, can result in unimaginable loss of human life.

Around the same time, Twitter deleted a post by Giuliani that it said violated its rules. The tweet, from March 27, made unfounded claims about the malaria drug hydroxychloroquine, one of the treatments that Trump has supported.

Hariri said that he has known Giuliani for years and that the appearance on his podcast was a friendly chat between people who know each other and who share a common interest in this particular response to this disease.

He said that he has no business relationship with Giuliani, and that Giuliani is not representing him in any way, either paid or unpaid.

I dont have anything to do with what the mayor tweets or whatnot, and I dont agree or disagree with anything, he said.

Hariri said the company would follow the established process for testing whether a drug works.

We have waited for the FDA to complete their review, which they did in a heroic and quick fashion, he said.

On Wednesday evening the same day the FDA approved his trial Hariri praised the appearance by the agencys commissioner, Dr. Stephen Hahn, on the conservative Fox News talk show The Ingraham Angle.

We are fortunate to have Dr. Hahn at the helm, he tweeted.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Coronavirus Outbreak News, download Indian Express App.

Read the original post:
Unproven Stem Cell Therapy Gets OK for Testing in Coronavirus Patients - The Indian Express

WASHINGTON, April 2, 2020 /PRNewswire/ -- An article published in Experimental Biology and Medicine (Volume 245, Issue 6, March 2020) (https://journals.sagepub.com/doi/pdf/10.1177/1535370220910690) examines the safety of stem cell therapy for the treatment of colon cancer.The study, led by Dr. J. Liu in the State Key Laboratory of Bioreactor Engineering and Shanghai Key Laboratory of New Drug Design at the East China University of Science and Technology in Shanghai (China), reports that mesenchymal stem cells from a variety of sources promote the growth and metastasis of colon cancer cells in an animal model.

Mesenchymal stem (MSCs), a category of adult stem cells, are being evaluated as therapy for numerous cancers.MSCs are excellent carriers for tumor treatment because they migrate to tumor tissues, can be genetically modified to secrete anticancer molecules and do not elicit immune responses.Clinical trials have shown that MSCs carrying modified genes can be used to treat colon cancer as well as ulcerative colitis. However, some studies have demonstrated MSCs can differentiate into cancer-associated fibroblasts and promote tumor growth.Therefore, additional studies are needed to evaluate the safety of MSCs for targeted treatment of colon cancer.

In the current study, Dr. Liu and colleagues examined the effects of mesenchymal stem cells (MSCs) from three sources (bone marrow, adipose and placenta) on colon cancer cells.MSCs from all three sources promoted tumor growth and metastasis in vivo. In vitro studies demonstrated that MSCs promote colon cancer cell stemness and epithelial to mesenchymal transition, which would enhance tumor growth and metastasis respectively.Finally, the detrimental effects of MSCs could be reversed by blocking IL-8 signaling pathways. Dr. Ma, co-author on the study, said that "Mesenchymal stem cells have a dual role: promoting and/or suppressing cancer. Which effect is dominant depends on the type of tumor cell, the tissue source of the MSC and the interaction between the MSC and the cancer cell. This is the major issue in the clinical application research of MSCs, and additional preclinical experimental data will be needed to evaluate the safety of MSCs for colon cancer treatment."

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology & Medicine, said: "Lui and colleagues have performed elegant studies on the impact of mesenchymal stem cells (MSCs), from various sources, upon the proliferation, stemness and metastasis of colon cancer stem cells (CSCs) in vitro and in vivo. They further demonstrate that IL-8 stimulates the interaction between colon CSCs and MSCs, and activates the MAPK signaling pathway in colon CSCs.This provides a basis for the further study of MSCs as a biologic therapy for colon cancer."

Experimental Biology and Medicine is a global journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences. The journal was first established in 1903. Experimental Biology and Medicine is the journal of the Society of Experimental Biology and Medicine. To learn about the benefits of society membership, visit http://www.sebm.org. For anyone interested in publishing in the journal, please visit http://ebm.sagepub.com.

Related Images

logo.png Logo

View original content to download multimedia:http://www.prnewswire.com/news-releases/stem-cell-therapy-for-colon-cancer-301033659.html

SOURCE Experimental Biology and Medicine

Read the rest here:
Stem Cell Therapy for Colon Cancer - Yahoo Finance

Dr. Bart Rademaker is announcing that he will host online classes on stem cell therapy and its impact on the coronavirus.

TAMPA, Fla., April 2, 2020 /PRNewswire-PRWeb/ -- Dr. Bart Rademaker, the long-time plastic surgeon who has branched out into stem cell therapy, is offering online classes to patients and doctors who are interested in learning more about regenerative medicine and the potential benefits on health in particular during this time with the coronavirus or COVID-19. Rademaker, has offered the therapy in his office for years and has been contacted by physicians and patients who wish to find out more information on the benefits it could have for those combating the virus as clinical trials are proceeding in many parts of the world.. The classes will be available beginning in April 2020 and include podcasts, blogs and other forms of information that are available online.

"The coronavirus has turned the world upside down and people are trying to gather any information they can. I've heard medical experts tell people to drink warm tea or water every 20 minutes. I've heard patients say they read that you can kill the virus with stem cell therapy. There is too much information going out there right now and I want to help patients and medical professionals get the facts on it. Based on my experience and my communication with experts in the field of regenerative medicine, I feel that I can offer some assistance." Dr. Bart Rademaker

One of the main things the doctor wishes to stress to people who are unsure how to minimize exposure is that they need to follow the guidelines put in place by their government and information provided on personal hygiene and safety. This includes washing hands thoroughly with water and soap rather than rely on hand soap. Trying to avoid contact with your eyes and mouth unless you've recently washed your hands. Taking vitamins to strengthen your immune system. Staying away from people and avoiding areas like grocery stores as long as possible are other good recommendations provided that people should follow.

"People are not sure what to do because the information comes at them so quickly. Even doctors are not sure when their patient asks them if stem cell therapy is a safe option to prevent or treat the coronavirus. When I have doctors calling me just because they saw that I offer regenerative medicine information online, I knew it was time to start getting aggressive with these classes and offer my assistance to everyone."

For more information you can call our team at: 727-748-7389

About Dr. Bart Rademaker

Dr. Bart Rademaker is based in Tampa, Florida and has over 20 years of experience as a well-respected medical professional. He has affiliations with several hospitals including Morton Plant and Mease Countryside. His degree is from Erasmus University Rotterdam Faculty of Medicine and added regenerative medicine to his practice four years ago.

SOURCE Dr. Bart Rademaker

See the rest here:
Dr. Bart Rademaker Offers Free Classes On Stem Cell Therapy And The Coronavirus - Yahoo Finance

SOUTH SAN FRANCISCO, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation(FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Fluidigm CyTOF technology was used in a clinical study producing preliminary evidence that mesenchymal stem cell (MSC) therapy improves outcomes in patients with COVID-19 pneumonia, providing key information about potential mechanisms of action of the treatment strategy.

Results of the study, conducted by researchers in China, have been published in Aging and Disease.1

We used a 36-marker CyTOF panel to generate a broad immune profile of each patients peripheral blood before and after transplantation, said Wenjing Wang, PhD, Associate Professor at Beijing Hepatology Research Institute, Youan Hospital. Mass cytometry allowed us to look at all immune populations of interest in a single tube of peripheral blood mononuclear cells, enabling us to use less sample and to simplify our workflow and analysis.

The study, which evaluated clinical outcomes as well as changes in inflammatory and immune function for 14 days in seven patients with COVID-19 pneumonia, indicated that intravenous transplantation of MSCs was a safe and effective treatment for patients with COVID-19 pneumonia, including for those in severe condition.

Pulmonary function and symptoms of these seven patients were significantly improved within two days of MSC transplantation. Three of the patients, including one classified as severe, recovered and were discharged 10 days after treatment.

CyTOF analysis found that MSC treatment of severe cases led to disappearance in three to six days of overactivated cytokine-secreting immune cells and increases in regulatory T and dendritic cells. Importantly, there was a dramatic increase in a population of CD14+CD11c+CD11bmidregulatory dendritic cells, which may have helped to tamp down the cytokine storm associated with COVID-19 respiratory disease. Separate analysis of patient serum found significant reduction in levels of TNF-, a potent inflammatory cytokine, while IL-10, an anti-inflammatory cytokine, increased in the MSC treatment group compared to the placebo control group.

This level of new and valuable treatment research based on broad-based immune profiling is an important front in the COVID-19 fight, said Chris Linthwaite, President and CEO of Fluidigm. Fluidigm is actively engaged with many researchers in government and medical institutions who are addressing the COVID-19 pandemic from the perspectives of both immune profiling and virus detection and testing, and this study underscores the critical role that our technologies are playing in the global response to the outbreak.

In addition to our instruments, our assays and analysis software are increasingly the focus of customers in the global research community exploring immune profiling of COVID-19 infected populations. Our Maxpar Direct Immune Profiling Assay and Maxpar Pathsetter analysis software are a solution for labs seeking an easily deployed, fixed panel that can incorporate novel exploratory markers as well as standard markers, Linthwaite said.

We are inspired by this opportunity to provide meaningful tools in efforts to develop innovative solutions to this rapidly evolving pandemic.

About FluidigmFluidigm(FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visitfluidigm.com.

Fluidigm, theFluidigmlogo, CyTOF, Direct, Immune Profiling Assay, Maxpar, and Pathsetter are trademarks and/or registered trademarks ofFluidigm Corporationinthe United Statesand/or other countries. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

Story continues

Forward-Looking Statements for FluidigmThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the implementation of Fluidigm microfluidics technology and products by third parties and the anticipated benefits of, and applications and demand for, such products. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to the potential adverse effects of the coronavirus pandemic on our business and operating results during 2020; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to company research and development and distribution plans and capabilities; interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affectingFluidigmbusiness and operating results is contained in Fluidigms Annual Report on Form 10-K for the year endedDecember 31, 2019, and in its other filings with theSecurities and Exchange Commission. These forward-looking statements speak only as of the date hereof.Fluidigmdisclaims any obligation to update these forward-looking statements except as may be required by law.

1 Leng, Z., Zhu, R., Hou, W. et al. Transplantation of ACE2 mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging and Disease 11 (2020): 216228.

Contacts:

Media:Mark SpearmanSenior Director, Corporate Communications650 243 6621mark.spearman@fluidigm.com

Investors:Agnes LeeVice President, Investor Relations650 416 7423agnes.lee@fluidigm.com

Read more here:
Fluidigm CyTOF Technology Used to Evaluate Stem Cell Therapy as a Potential Treatment for COVID-19 Pneumonia - Yahoo Finance

Nerve Repair and Regeneration market worldwide is projected to grow by US$7. 1 Billion, driven by a compounded growth of 12. 1%. Neurostimulation & Neuromodulation Devices, one of the segments analyzed and sized in this study, displays the potential to grow at over 12.

New York, April 02, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Nerve Repair and Regeneration Industry" - https://www.reportlinker.com/p05799212/?utm_source=GNW 3%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$11.8 Billion by the year 2025, Neurostimulation & Neuromodulation Devices will bring in healthy gains adding significant momentum to global growth.

- Representing the developed world, the United States will maintain a 11% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$339.2 Million to the regions size and clout in the next 5 to 6 years. Over US$405.8 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Neurostimulation & Neuromodulation Devices will reach a market size of US$527.3 Million by the close of the analysis period. As the worlds second largest economy and the new game changer in global markets, China exhibits the potential to grow at 16.1% over the next couple of years and add approximately US$1.4 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

- Competitors identified in this market include, among others,

Read the full report: https://www.reportlinker.com/p05799212/?utm_source=GNW

NERVE REPAIR AND REGENERATION MCP13MARKET ANALYSIS, TRENDS, AND FORECASTS, FEBRUARY 2CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW Nerve Repair and Regeneration Market Set for a Rapid Growth Neurostimulation and Neuromodulation Devices: Largest Product Segment Biomaterials to Exhibit Rapid Growth Nerve Repair and Regeneration Market by Application US and Europe Dominate the Market, Asia-Pacific to Register the Fastest Growth

2. FOCUS ON SELECT PLAYERS Abbott Laboratories, Inc. (USA) AxoGen, Inc. (USA) Boston Scientific Corporation (USA) Integra LifeSciences Corporation (USA) LivaNova, PLC (UK) Medtronic plc (USA) NeuroPace, Inc. (USA) Nevro Corporation.(USA) Orthomed S.A.S. (France) Polyganics B.V. (The Netherlands) Stryker Corporation (U.S.) Synapse Biomedical Inc. (U.S.) Synovis Micro Companies Alliance, Inc. (USA)

3. MARKET TRENDS & DRIVERS High Incidence of Brain Disorders and Nerve Injuries: Primary Market Driver EXHIBIT 1: Annual Incidence of Adult-Onset Neurologic Disorders in the US EXHIBIT 2: Symptomatic Epilepsy Incidence by Type (2019): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy EXHIBIT 3: Global Alzheimer's Prevalence by Age Group EXHIBIT 4: Diagnosed Prevalence Cases of Parkinsons Disease Across Select Countries Classification of Nerve Injuries Recent Developments in Spinal Cord Injury Treatment Rising Geriatric Population and Subsequent Growth in Prevalence Of Neurological Disorders EXHIBIT 5: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2and 2050 Intensified Research Activity Across Various Neural Disciplines Induces Additional Optimism Stem Cell Therapy: A Promising Avenue for Nerve Repair and Regeneration New Biomaterials Pave the Way for Innovative Neurodegeneration Therapies Role of Nerve Conduits in the Treatment of Peripheral Nerve Injury Innovative Nerve Conduits from Stryker Technological Advancements and Product Innovations - A Key Growth Driver Neurostimulation Allows Paralyzed People to Regain Leg Movement Neurostimulator to Treat Neurological Conditions Micro-Implantable Solution for Neurostimulation Parasym Device for Neurostimulation Boston Scientifics Spinal Cord Stimulation Improves Quality of Life Intellis Platform Presents Smallest Implantable Neurostimulator Innovation in Deep Brain Stimulation for Parkinsons Disease Innovations in Spinal Cord Stimulation for Pain Smart Neuromodulation: The Combination of AI and Neuromodulation Technologies New Dynamic Lead Interface Design for Neurostimulator Devices Wireless SCS Neuromodulation Therapy: An Alternative to Traditional SCS System Select Recent Approvals of Neuro-stimulation and Neuromodulation Devices Select Launches in Spinal Cord Stimulation (SCS) Market Select Launches in Deep Brain Stimulation (DBS) Market Select Neurostimulation Devices in Clinical Trials Select Neuromodulation Devices in Clinical Trials

4. GLOBAL MARKET PERSPECTIVE Table 1: Nerve Repair and Regeneration Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 2: Nerve Repair and Regeneration Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2009-2017 Table 3: Nerve Repair and Regeneration Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 Table 4: Neurostimulation & Neuromodulation Devices (Product) World Market by Region/Country in US$ Thousand: 2018 to 2025 Table 5: Neurostimulation & Neuromodulation Devices (Product) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017 Table 6: Neurostimulation & Neuromodulation Devices (Product) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 Table 7: Biomaterials (Product) Potential Growth Markets Worldwide in US$ Thousand: 2018 to 2025 Table 8: Biomaterials (Product) Historic Market Perspective by Region/Country in US$ Thousand: 2009 to 2017 Table 9: Biomaterials (Product) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 Table 10: Neurostimulation & Neuromodulation Surgeries (Application) Global Market Estimates & Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 11: Neurostimulation & Neuromodulation Surgeries (Application) Retrospective Demand Analysis in US$ Thousand by Region/Country: 2009-2017 Table 12: Neurostimulation & Neuromodulation Surgeries (Application) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 Table 13: Neurorrhaphy (Application) Demand Potential Worldwide in US$ Thousand by Region/Country: 2018-2025 Table 14: Neurorrhaphy (Application) Historic Sales Analysis in US$ Thousand by Region/Country: 2009-2017 Table 15: Neurorrhaphy (Application) Share Breakdown Review by Region/Country: 2009 VS 2019 VS 2025 Table 16: Nerve Grafting (Application) Worldwide Latent Demand Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 17: Nerve Grafting (Application) Global Historic Analysis in US$ Thousand by Region/Country: 2009-2017 Table 18: Nerve Grafting (Application) Distribution of Global Sales by Region/Country: 2009 VS 2019 VS 2025 Table 19: Stem Cell Therapy (Application) Sales Estimates and Forecasts in US$ Thousand by Region/Country for the Years 2through 2025 Table 20: Stem Cell Therapy (Application) Analysis of Historic Sales in US$ Thousand by Region/Country for the Years 2009 to 2017 Table 21: Stem Cell Therapy (Application) Global Market Share Distribution by Region/Country for 2009, 2019, and 2025 Table 22: Hospitals & Clinics (End-Use) Global Opportunity Assessment in US$ Thousand by Region/Country: 2018-2025 Table 23: Hospitals & Clinics (End-Use) Historic Sales Analysis in US$ Thousand by Region/Country: 2009-2017 Table 24: Hospitals & Clinics (End-Use) Percentage Share Breakdown of Global Sales by Region/Country: 2009 VS 2019 VS 2025 Table 25: Ambulatory Surgery Centers (End-Use) Worldwide Sales in US$ Thousand by Region/Country: 2018-2025 Table 26: Ambulatory Surgery Centers (End-Use) Historic Demand Patterns in US$ Thousand by Region/Country: 2009-2017 Table 27: Ambulatory Surgery Centers (End-Use) Market Share Shift across Key Geographies: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Table 28: United States Nerve Repair and Regeneration Market Estimates and Projections in US$ Thousand by Product: 2018 to 2025 Table 29: Nerve Repair and Regeneration Market in the United States by Product: A Historic Review in US$ Thousand for 2009-2017 Table 30: United States Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 31: United States Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025 Table 32: Nerve Repair and Regeneration Historic Demand Patterns in the United States by Application in US$ Thousand for 2009-2017 Table 33: Nerve Repair and Regeneration Market Share Breakdown in the United States by Application: 2009 VS 2019 VS 2025 Table 34: United States Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 Table 35: Nerve Repair and Regeneration Historic Demand Patterns in the United States by End-Use in US$ Thousand for 2009-2017 Table 36: Nerve Repair and Regeneration Market Share Breakdown in the United States by End-Use: 2009 VS 2019 VS 2025 CANADA Table 37: Canadian Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018 to 2025 Table 38: Canadian Nerve Repair and Regeneration Historic Market Review by Product in US$ Thousand: 2009-2017 Table 39: Nerve Repair and Regeneration Market in Canada: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 40: Canadian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025 Table 41: Nerve Repair and Regeneration Market in Canada: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2009-2017 Table 42: Canadian Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 43: Canadian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2to 2025 Table 44: Nerve Repair and Regeneration Market in Canada: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 Table 45: Canadian Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 JAPAN Table 46: Japanese Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Thousand by Product for the Period 2018-2025 Table 47: Nerve Repair and Regeneration Market in Japan: Historic Sales Analysis in US$ Thousand by Product for the Period 2009-2017 Table 48: Japanese Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 49: Japanese Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 50: Japanese Nerve Repair and Regeneration Market in US$ Thousand by Application: 2009-2017 Table 51: Nerve Repair and Regeneration Market Share Shift in Japan by Application: 2009 VS 2019 VS 2025 Table 52: Japanese Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 53: Japanese Nerve Repair and Regeneration Market in US$ Thousand by End-Use: 2009-2017 Table 54: Nerve Repair and Regeneration Market Share Shift in Japan by End-Use: 2009 VS 2019 VS 2025 CHINA Table 55: Chinese Nerve Repair and Regeneration Market Growth Prospects in US$ Thousand by Product for the Period 2018-2025 Table 56: Nerve Repair and Regeneration Historic Market Analysis in China in US$ Thousand by Product: 2009-2017 Table 57: Chinese Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 58: Chinese Demand for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 59: Nerve Repair and Regeneration Market Review in China in US$ Thousand by Application: 2009-2017 Table 60: Chinese Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 Table 61: Chinese Demand for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 62: Nerve Repair and Regeneration Market Review in China in US$ Thousand by End-Use: 2009-2017 Table 63: Chinese Nerve Repair and Regeneration Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 EUROPE Table 64: European Nerve Repair and Regeneration Market Demand Scenario in US$ Thousand by Region/Country: 2018-2025 Table 65: Nerve Repair and Regeneration Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2009-2017 Table 66: European Nerve Repair and Regeneration Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 Table 67: European Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018-2025 Table 68: Nerve Repair and Regeneration Market in Europe in US$ Thousand by Product: A Historic Review for the Period 2009-2017 Table 69: European Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 70: European Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by Application: 2018-2025 Table 71: Nerve Repair and Regeneration Market in Europe: Summarization of Historic Demand in US$ Thousand by Application for the Period 2009-2017 Table 72: European Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 73: European Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 Table 74: Nerve Repair and Regeneration Market in Europe: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 Table 75: European Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 FRANCE Table 76: Nerve Repair and Regeneration Market in France by Product: Estimates and Projections in US$ Thousand for the Period 2018-2025 Table 77: French Nerve Repair and Regeneration Historic Market Scenario in US$ Thousand by Product: 2009-2017 Table 78: French Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 79: Nerve Repair and Regeneration Quantitative Demand Analysis in France in US$ Thousand by Application: 2018-2025 Table 80: French Nerve Repair and Regeneration Historic Market Review in US$ Thousand by Application: 2009-2017 Table 81: French Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 Table 82: Nerve Repair and Regeneration Quantitative Demand Analysis in France in US$ Thousand by End-Use: 2018-2025 Table 83: French Nerve Repair and Regeneration Historic Market Review in US$ Thousand by End-Use: 2009-2017 Table 84: French Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by End-Use for 2009, 2019, and 2025 GERMANY Table 85: Nerve Repair and Regeneration Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 86: German Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 87: German Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 88: Nerve Repair and Regeneration Market in Germany: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025 Table 89: German Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by Application: 2009-2017 Table 90: Nerve Repair and Regeneration Market Share Distribution in Germany by Application: 2009 VS 2019 VS 2025 Table 91: Nerve Repair and Regeneration Market in Germany: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 Table 92: German Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by End-Use: 2009-2017 Table 93: Nerve Repair and Regeneration Market Share Distribution in Germany by End-Use: 2009 VS 2019 VS 2025 ITALY Table 94: Italian Nerve Repair and Regeneration Market Growth Prospects in US$ Thousand by Product for the Period 2018-2025 Table 95: Nerve Repair and Regeneration Historic Market Analysis in Italy in US$ Thousand by Product: 2009-2017 Table 96: Italian Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 97: Italian Demand for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 98: Nerve Repair and Regeneration Market Review in Italy in US$ Thousand by Application: 2009-2017 Table 99: Italian Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 Table 100: Italian Demand for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 101: Nerve Repair and Regeneration Market Review in Italy in US$ Thousand by End-Use: 2009-2017 Table 102: Italian Nerve Repair and Regeneration Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 UNITED KINGDOM Table 103: United Kingdom Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Thousand by Product for the Period 2018-2025 Table 104: Nerve Repair and Regeneration Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Product for the Period 2009-2017 Table 105: United Kingdom Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 106: United Kingdom Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 107: United Kingdom Nerve Repair and Regeneration Market in US$ Thousand by Application: 2009-2017 Table 108: Nerve Repair and Regeneration Market Share Shift in the United Kingdom by Application: 2009 VS 2019 VS 2025 Table 109: United Kingdom Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2to 2025 Table 110: United Kingdom Nerve Repair and Regeneration Market in US$ Thousand by End-Use: 2009-2017 Table 111: Nerve Repair and Regeneration Market Share Shift in the United Kingdom by End-Use: 2009 VS 2019 VS 2025 SPAIN Table 112: Spanish Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018 to 2025 Table 113: Spanish Nerve Repair and Regeneration Historic Market Review by Product in US$ Thousand: 2009-2017 Table 114: Nerve Repair and Regeneration Market in Spain: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 115: Spanish Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025 Table 116: Nerve Repair and Regeneration Market in Spain: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2009-2017 Table 117: Spanish Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 118: Spanish Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2to 2025 Table 119: Nerve Repair and Regeneration Market in Spain: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 Table 120: Spanish Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 RUSSIA Table 121: Russian Nerve Repair and Regeneration Market Estimates and Projections in US$ Thousand by Product: 2018 to 2025 Table 122: Nerve Repair and Regeneration Market in Russia by Product: A Historic Review in US$ Thousand for 2009-2017 Table 123: Russian Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 124: Russian Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025 Table 125: Nerve Repair and Regeneration Historic Demand Patterns in Russia by Application in US$ Thousand for 2009-2017 Table 126: Nerve Repair and Regeneration Market Share Breakdown in Russia by Application: 2009 VS 2019 VS 2025 Table 127: Russian Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 Table 128: Nerve Repair and Regeneration Historic Demand Patterns in Russia by End-Use in US$ Thousand for 2009-2017 Table 129: Nerve Repair and Regeneration Market Share Breakdown in Russia by End-Use: 2009 VS 2019 VS 2025 REST OF EUROPE Table 130: Rest of Europe Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018-2025 Table 131: Nerve Repair and Regeneration Market in Rest of Europe in US$ Thousand by Product: A Historic Review for the Period 2009-2017 Table 132: Rest of Europe Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 133: Rest of Europe Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by Application: 2018-2025 Table 134: Nerve Repair and Regeneration Market in Rest of Europe: Summarization of Historic Demand in US$ Thousand by Application for the Period 2009-2017 Table 135: Rest of Europe Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 136: Rest of Europe Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 Table 137: Nerve Repair and Regeneration Market in Rest of Europe: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 Table 138: Rest of Europe Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 ASIA-PACIFIC Table 139: Asia-Pacific Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 140: Nerve Repair and Regeneration Market in Asia-Pacific: Historic Market Analysis in US$ Thousand by Region/Country for the Period 2009-2017 Table 141: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025 Table 142: Nerve Repair and Regeneration Market in Asia-Pacific by Product: Estimates and Projections in US$ Thousand for the Period 2018-2025 Table 143: Asia-Pacific Nerve Repair and Regeneration Historic Market Scenario in US$ Thousand by Product: 2009-2017 Table 144: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 145: Nerve Repair and Regeneration Quantitative Demand Analysis in Asia-Pacific in US$ Thousand by Application: 2018-2025 Table 146: Asia-Pacific Nerve Repair and Regeneration Historic Market Review in US$ Thousand by Application: 2009-2017 Table 147: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 Table 148: Nerve Repair and Regeneration Quantitative Demand Analysis in Asia-Pacific in US$ Thousand by End-Use: 2018-2025 Table 149: Asia-Pacific Nerve Repair and Regeneration Historic Market Review in US$ Thousand by End-Use: 2009-2017 Table 150: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by End-Use for 2009, 2019, and 2025 AUSTRALIA Table 151: Nerve Repair and Regeneration Market in Australia: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 152: Australian Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 153: Australian Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 154: Nerve Repair and Regeneration Market in Australia: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025 Table 155: Australian Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by Application: 2009-2017 Table 156: Nerve Repair and Regeneration Market Share Distribution in Australia by Application: 2009 VS 2019 VS 2025 Table 157: Nerve Repair and Regeneration Market in Australia: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 Table 158: Australian Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by End-Use: 2009-2017 Table 159: Nerve Repair and Regeneration Market Share Distribution in Australia by End-Use: 2009 VS 2019 VS 2025 INDIA Table 160: Indian Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018 to 2025 Table 161: Indian Nerve Repair and Regeneration Historic Market Review by Product in US$ Thousand: 2009-2017 Table 162: Nerve Repair and Regeneration Market in India: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 163: Indian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025 Table 164: Nerve Repair and Regeneration Market in India: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2009-2017 Table 165: Indian Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 166: Indian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2to 2025 Table 167: Nerve Repair and Regeneration Market in India: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 Table 168: Indian Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 SOUTH KOREA Table 169: Nerve Repair and Regeneration Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 170: South Korean Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 171: Nerve Repair and Regeneration Market Share Distribution in South Korea by Product: 2009 VS 2019 VS 2025 Table 172: Nerve Repair and Regeneration Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by Application for the Period 2018-2025 Table 173: South Korean Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Application: 2009-2017 Table 174: Nerve Repair and Regeneration Market Share Distribution in South Korea by Application: 2009 VS 2019 VS 2025 Table 175: Nerve Repair and Regeneration Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by End-Use for the Period 2018-2025 Table 176: South Korean Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by End-Use: 2009-2017 Table 177: Nerve Repair and Regeneration Market Share Distribution in South Korea by End-Use: 2009 VS 2019 VS 2025 REST OF ASIA-PACIFIC Table 178: Rest of Asia-Pacific Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Thousand by Product for the Period 2018-2025 Table 179: Nerve Repair and Regeneration Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Thousand by Product for the Period 2009-2017 Table 180: Rest of Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 181: Rest of Asia-Pacific Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 182: Rest of Asia-Pacific Nerve Repair and Regeneration Market in US$ Thousand by Application: 2009-2017 Table 183: Nerve Repair and Regeneration Market Share Shift in Rest of Asia-Pacific by Application: 2009 VS 2019 VS 2025 Table 184: Rest of Asia-Pacific Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 185: Rest of Asia-Pacific Nerve Repair and Regeneration Market in US$ Thousand by End-Use: 2009-2017 Table 186: Nerve Repair and Regeneration Market Share Shift in Rest of Asia-Pacific by End-Use: 2009 VS 2019 VS 2025 LATIN AMERICA Table 187: Latin American Nerve Repair and Regeneration Market Trends by Region/Country in US$ Thousand: 2018-2025 Table 188: Nerve Repair and Regeneration Market in Latin America in US$ Thousand by Region/Country: A Historic Perspective for the Period 2009-2017 Table 189: Latin American Nerve Repair and Regeneration Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025 Table 190: Latin American Nerve Repair and Regeneration Market Growth Prospects in US$ Thousand by Product for the Period 2018-2025 Table 191: Nerve Repair and Regeneration Historic Market Analysis in Latin America in US$ Thousand by Product: 2009-2017 Table 192: Latin American Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 193: Latin American Demand for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 194: Nerve Repair and Regeneration Market Review in Latin America in US$ Thousand by Application: 2009-2017 Table 195: Latin American Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 Table 196: Latin American Demand for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 197: Nerve Repair and Regeneration Market Review in Latin America in US$ Thousand by End-Use: 2009-2017 Table 198: Latin American Nerve Repair and Regeneration Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 ARGENTINA Table 199: Argentinean Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018-2025 Table 200: Nerve Repair and Regeneration Market in Argentina in US$ Thousand by Product: A Historic Review for the Period 2009-2017 Table 201: Argentinean Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 202: Argentinean Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by Application: 2018-2025 Table 203: Nerve Repair and Regeneration Market in Argentina: Summarization of Historic Demand in US$ Thousand by Application for the Period 2009-2017 Table 204: Argentinean Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 205: Argentinean Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 Table 206: Nerve Repair and Regeneration Market in Argentina: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 Table 207: Argentinean Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 BRAZIL Table 208: Nerve Repair and Regeneration Market in Brazil by Product: Estimates and Projections in US$ Thousand for the Period 2018-2025 Table 209: Brazilian Nerve Repair and Regeneration Historic Market Scenario in US$ Thousand by Product: 2009-2017 Table 210: Brazilian Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 211: Nerve Repair and Regeneration Quantitative Demand Analysis in Brazil in US$ Thousand by Application: 2018-2025 Table 212: Brazilian Nerve Repair and Regeneration Historic Market Review in US$ Thousand by Application: 2009-2017 Table 213: Brazilian Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 Table 214: Nerve Repair and Regeneration Quantitative Demand Analysis in Brazil in US$ Thousand by End-Use: 2018-2025 Table 215: Brazilian Nerve Repair and Regeneration Historic Market Review in US$ Thousand by End-Use: 2009-2017 Table 216: Brazilian Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by End-Use for 2009, 2019, and 2025 MEXICO Table 217: Nerve Repair and Regeneration Market in Mexico: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 218: Mexican Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 219: Mexican Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 220: Nerve Repair and Regeneration Market in Mexico: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025 Table 221: Mexican Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by Application: 2009-2017 Table 222: Nerve Repair and Regeneration Market Share Distribution in Mexico by Application: 2009 VS 2019 VS 2025 Table 223: Nerve Repair and Regeneration Market in Mexico: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 Table 224: Mexican Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by End-Use: 2009-2017 Table 225: Nerve Repair and Regeneration Market Share Distribution in Mexico by End-Use: 2009 VS 2019 VS 2025 REST OF LATIN AMERICA Table 226: Rest of Latin America Nerve Repair and Regeneration Market Estimates and Projections in US$ Thousand by Product: 2018 to 2025 Table 227: Nerve Repair and Regeneration Market in Rest of Latin America by Product: A Historic Review in US$ Thousand for 2009-2017 Table 228: Rest of Latin America Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 229: Rest of Latin America Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025 Table 230: Nerve Repair and Regeneration Historic Demand Patterns in Rest of Latin America by Application in US$ Thousand for 2009-2017 Table 231: Nerve Repair and Regeneration Market Share Breakdown in Rest of Latin America by Application: 2009 VS 2019 VS 2025 Table 232: Rest of Latin America Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 Table 233: Nerve Repair and Regeneration Historic Demand Patterns in Rest of Latin America by End-Use in US$ Thousand for 2009-2017 Table 234: Nerve Repair and Regeneration Market Share Breakdown in Rest of Latin America by End-Use: 2009 VS 2019 VS 2025 MIDDLE EAST Table 235: The Middle East Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 236: Nerve Repair and Regeneration Market in the Middle East by Region/Country in US$ Thousand: 2009-2017 Table 237: The Middle East Nerve Repair and Regeneration Market Share Breakdown by Region/Country: 2009, 2019, and 2025 Table 238: The Middle East Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018 to 2025 Table 239: The Middle East Nerve Repair and Regeneration Historic Market by Product in US$ Thousand: 2009-2017 Table 240: Nerve Repair and Regeneration Market in the Middle East: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 241: The Middle East Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025 Table 242: Nerve Repair and Regeneration Market in the Middle East: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2009-2017 Table 243: The Middle East Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 244: The Middle East Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2to 2025 Table 245: Nerve Repair and Regeneration Market in the Middle East: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 Table 246: The Middle East Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 IRAN Table 247: Iranian Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Thousand by Product for the Period 2018-2025 Table 248: Nerve Repair and Regeneration Market in Iran: Historic Sales Analysis in US$ Thousand by Product for the Period 2009-2017 Table 249: Iranian Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 250: Iranian Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 251: Iranian Nerve Repair and Regeneration Market in US$ Thousand by Application: 2009-2017 Table 252: Nerve Repair and Regeneration Market Share Shift in Iran by Application: 2009 VS 2019 VS 2025 Table 253: Iranian Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 254: Iranian Nerve Repair and Regeneration Market in US$ Thousand by End-Use: 2009-2017 Table 255: Nerve Repair and Regeneration Market Share Shift in Iran by End-Use: 2009 VS 2019 VS 2025 ISRAEL Table 256: Israeli Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018-2025 Table 257: Nerve Repair and Regeneration Market in Israel in US$ Thousand by Product: A Historic Review for the Period 2009-2017 Table 258: Israeli Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 259: Israeli Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by Application: 2018-2025 Table 260: Nerve Repair and Regeneration Market in Israel: Summarization of Historic Demand in US$ Thousand by Application for the Period 2009-2017 Table 261: Israeli Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 262: Israeli Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 Table 263: Nerve Repair and Regeneration Market in Israel: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 Table 264: Israeli Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 SAUDI ARABIA Table 265: Saudi Arabian Nerve Repair and Regeneration Market Growth Prospects in US$ Thousand by Product for the Period 2018-2025 Table 266: Nerve Repair and Regeneration Historic Market Analysis in Saudi Arabia in US$ Thousand by Product: 2009-2017 Table 267: Saudi Arabian Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 268: Saudi Arabian Demand for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 269: Nerve Repair and Regeneration Market Review in Saudi Arabia in US$ Thousand by Application: 2009-2017 Table 270: Saudi Arabian Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 Table 271: Saudi Arabian Demand for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 272: Nerve Repair and Regeneration Market Review in Saudi Arabia in US$ Thousand by End-Use: 2009-2017 Table 273: Saudi Arabian Nerve Repair and Regeneration Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 UNITED ARAB EMIRATES Table 274: Nerve Repair and Regeneration Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 275: United Arab Emirates Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 276: Nerve Repair and Regeneration Market Share Distribution in United Arab Emirates by Product: 2009 VS 2VS 2025 Table 277: Nerve Repair and Regeneration Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by Application for the Period 2018-2025 Table 278: United Arab Emirates Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Application: 2009-2017 Table 279: Nerve Repair and Regeneration Market Share Distribution in United Arab Emirates by Application: 2009 VS 2019 VS 2025 Table 280: Nerve Repair and Regeneration Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by End-Use for the Period 2018-2025 Table 281: United Arab Emirates Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by End-Use: 2009-2017 Table 282: Nerve Repair and Regeneration Market Share Distribution in United Arab Emirates by End-Use: 2009 VS 2VS 2025 REST OF MIDDLE EAST Table 283: Nerve Repair and Regeneration Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 284: Rest of Middle East Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 285: Rest of Middle East Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 286: Nerve Repair and Regeneration Market in Rest of Middle East: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025 Table 287: Rest of Middle East Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by Application: 2009-2017 Table 288: Nerve Repair and Regeneration Market Share Distribution in Rest of Middle East by Application: 2009 VS 2019 VS 2025 Table 289: Nerve Repair and Regeneration Market in Rest of Middle East: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 Table 290: Rest of Middle East Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by End-Use: 2009-2017 Table 291: Nerve Repair and Regeneration Market Share Distribution in Rest of Middle East by End-Use: 2009 VS 2019 VS 2025 AFRICA Table 292: African Nerve Repair and Regeneration Market Estimates and Projections in US$ Thousand by Product: 2018 to 2025 Table 293: Nerve Repair and Regeneration Market in Africa by Product: A Historic Review in US$ Thousand for 2009-2017 Table 294: African Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 295: African Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025 Table 296: Nerve Repair and Regeneration Historic Demand Patterns in Africa by Application in US$ Thousand for 2009-2017 Table 297: Nerve Repair and Regeneration Market Share Breakdown in Africa by Application: 2009 VS 2019 VS 2025 Table 298: African Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 Table 299: Nerve Repair and Regeneration Historic Demand Patterns in Africa by End-Use in US$ Thousand for 2009-2017 Table 300: Nerve Repair and Regeneration Market Share Breakdown in Africa by End-Use: 2009 VS 2019 VS 2025

IV. COMPETITION

Total Companies Profiled:

Read the full report: https://www.reportlinker.com/p05799212/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

See the original post:
Global Nerve Repair and Regeneration Industry - Yahoo Finance

According to Masud Soleimani, who recently came home from illegal detainment in US, the research is being carried out with the support of the Health Ministry in two Tehran-based hospitals of Shariati and Masih Daneshvari.

The news came as some local media had earlier quoted Soleimani as saying that a drug for the disease has been developed.

In an interview with Mehr News Agency on Saturday night, Soleimani dismissed the reports as inaccurate, noting that this is not a drug but a method that is still being worked on.

The results of the first phase of its clinical trial will be announced soon by the Health Ministry, he added.

According to the latest announcement on Saturday, the number of confirmed cases of the COVID-19 has hit 35,408 in the country. 11,679 patients have recovered so far while the virus has claims 2,517 lives.

MAH/ 4888035

See the original post here:
Iranian scientists working on stem cell therapy to treat Covid-19 patients - Mehr News Agency - English Version

LONDON--(BUSINESS WIRE)--The global autologous cell therapy market is poised to grow by USD 1.97 billion during 2020-2024, progressing at a CAGR of almost 22% during the forecast period. Request free sample pages

Read the 120-page report with TOC on "Autologous Cell Therapy Market Analysis Report by Therapy (Autologous stem cell therapy and Autologous cellular immunotherapies), Application (Oncology, Musculoskeletal disorders, and Dermatology), Geography (North America, APAC, Europe, South America, and MEA), and the Segment Forecasts, 2020-2024".

https://www.technavio.com/report/autologous-cell-therapy-market-industry-analysis

The market is driven by the increasing demand for effective drugs for cardiac and degenerative disorders. In addition, the limitations in traditional organ transplantations are fueling the demand for stem cell therapies. All these factors are anticipated to boost the growth of the autologous cell therapy market.

The demand for effective drugs for cardiac and degenerative disorders has been increasing across the world. In addition, the discovery of possible cardiac autologous cells has enabled vendors to develop novel drugs for the treatment of various cardiac diseases. For instance, Mesoblast is developing MPC-150-IM. It is a Phase III candidate for the treatment of advanced and end-stage chronic heart failure. Similarly, Shire has been developing autologous stem cell therapies for chronic myocardial ischemia. These products are expected to be launched during the forecast period and will have a positive impact on the growth of the global autologous cell therapy market.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Autologous Cell Therapy Market Companies:

Bayer AG

Bayer AG operates its business through segments such as Pharmaceuticals, Crop Science, Consumer Health, and Animal Health. The company offers induced pluripotent stem cells. They are developed by reprogramming mature body cells to behave like embryonic stem cells that are injected to restore diseased tissue in patients.

Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc. operates its business through an unified business segment. NurOwn is the key offering of the company. It is a cell therapy platform, which develops mesenchymal stem cells for the treatment of human diseases such as immune and inflammatory diseases.

Daiichi Sankyo Co. Ltd.

Daiichi Sankyo Co. Ltd. operates its business through segments such as Innovative Pharmaceuticals, Generic, Vaccine, and OTC Related. Heartcel is the key offering of the company. It is an immune-modulatory progenitor cell therapeutic agent, which is used for ischemic heart failure.

FUJIFILM Holdings Corp.

FUJIFILM Holdings Corp. operates its business through segments such as Imaging solutions, Healthcare and material solutions, and Document solutions. The company uses induced pluripotent stem cells to derive differentiated cells, which are used in researching various diseases and conditions.

Holostem Terapie Avanzate Srl

Holostem Terapie Avanzate Srl operates its business through an unified business segment. Holoclar is the key offering of the company. It is an advanced therapy medicinal product containing stem cells indicated to repair the cornea after injury.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Autologous Cell Therapy Market Therapy Outlook (Revenue, USD Billion, 2020-2024)

Autologous Cell Therapy Market Application Outlook (Revenue, USD Billion, 2020-2024)

Autologous Cell Therapy Market Regional Outlook (Revenue, USD Billion, 2020-2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.

Request a free sample report

Related Reports on Healthcare Include:

Global Cancer Stem Cell Therapeutics Market Global cancer stem cell therapy market by type (allogeneic stem cell transplant and autologous stem cell transplant) and geography (Asia, Europe, North America, and ROW).

Global Mantle Cell Lymphoma Therapeutics Market Global mantle cell lymphoma therapeutics market by product (combination therapy and monotherapy) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Link:
Global Autologous Cell Therapy Market 2020-2024 | Evolving Opportunities with Bayer AG and Brainstorm Cell Therapeutics Inc. | Technavio - Business...

It is a universally acknowledged fact that the majority of women refuse to age, the moment they reach the age of 40. The desire to turn back the clock is something that gets automatically etched on their minds, after hitting middle age. Making a wise choice from the wide range of anti-ageing solutions available for women can be a highly baffling affair, but understanding the skins needs is equally crucial.

So what exactly is ageing, that every person, especially women dread? It can be regarded as a complex process resulting in accrual changes in a persons body over. a period of time. Ageing occurs in fractions, because the stem cells which have the ability to renew themselves grow old as DNA gets damaged and changes occur in the overall physiology. As time passes by and people age, the majority of the cells present in their bodies get replaced and the ability of the body to produce more new cells gradually declines, Thus, anti-ageing retards the degeneration process of the body.

Post an anti-ageing fat stem cell treatment the skin shows prominent signs of turning softer while the body notices a remarkable surge of energy, resulting in improved sleeping and breathing patterns, controlled sugar levels, rebalanced hormones, increased metabolism, average weight loss and fading age spots. This all seems possible owing to the insertion of 30-50 million supercharged active stem cells.

Ageing is indeed complex, as its causes have not yet been completely understood. A big part of ageing occurs when the body is being attacked by inflammation and oxidative stress. Even though it is said that ageing is a natural process which is unavoidable, there is still scope to maintain health and stay young for both preventing age-related diseases and to enjoy the benefits of youth.

The desire to be younger is not exactly a new idea. The concept of anti-ageing has kept humankind occupied since ages, with the idea about staying healthy and fit with age and improving the quality of life. So with the rising evidence about the association of ageing diseases with adult stem cell exhaustion, it will not be surprising to witness an elevation of interest towards restoring the adult stem cell function to improve these conditions and to turn back the clock!

Read the rest here:
Reversing The Ageing Process With Stem Cell Therapy - Version Weekly

New Jersey, United States:The Stem Cell Therapy Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the Stem Cell Therapy market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the Stem Cell Therapy Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the Stem Cell Therapy market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the Stem Cell Therapy market.

Global Stem Cell TherapyMarketwas valued at USD 86.62 million in 2016 and is projected to reach USD 221.03million by 2025, growing at a CAGR of 10.97% from 2017 to 2025.

Leading players of the Stem Cell Therapy market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the Stem Cell Therapy market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the Stem Cell Therapy market. It also provides useful recommendations for new as well as established players of the Stem Cell Therapy market.

Stem Cell Therapy Market by Regional Segments:

The chapter on regional segmentation describes the regional aspects of the Stem Cell Therapy market. This chapter explains the regulatory framework that is expected to affect the entire market. It illuminates the political scenario of the market and anticipates its impact on the market for Stem Cell Therapy.

Analysts who have authored the report have segmented the market for Stem Cell Therapy by product, application and region. All segments are the subject of extensive research, with a focus on CAGR, market size, growth potential, market share and other important factors. The segment study provided in the report will help players focus on the lucrative areas of the Stem Cell Therapy market. The regional analysis will help the actors to strengthen their position in the most important regional markets. It shows unused growth opportunities in regional markets and how they can be used in the forecast period.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=SGN&utm_medium=003

Highlights of TOC:

Overview: In addition to an overview of the Stem Cell Therapy market, this section provides an overview of the report to give an idea of the type and content of the study.

Market dynamics: Here the authors of the report discussed in detail the main drivers, restrictions, challenges, trends and opportunities in the market for Stem Cell Therapy.

Product Segments: This part of the report shows the growth of the market for various types of products sold by the largest companies.

Application segments: The analysts who have authored the report have thoroughly evaluated the market potential of the key applications and identified the future opportunities they should create in the Stem Cell Therapy.

Geographic Segments: Each regional market is carefully examined to understand its current and future growth scenarios.

Company Profiles: The top players in the Stem Cell Therapy market are detailed in the report based on their market share, served market, products, applications, regional growth and other factors.

The report also includes specific sections on production and consumption analysis, key results, key suggestions and recommendations, and other issues. Overall, it offers a complete analysis and research study of the Stem Cell Therapy market to help players ensure strong growth in the coming years.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=SGN&utm_medium=003

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes; Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Tags: Stem Cell Therapy Market Size, Stem Cell Therapy Market Trends, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Analysis

Our Trending Reports

Laser Pointer Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read the original:
Stem Cell Therapy Market 2020 | Growing Rapidly with Significant CAGR, Leading Players, Innovative Trends and Expected Revenue by 2026 - Skyline...

The electronic newsletter I Love My Freedom on a regular basis blasts out e-mails hawking ostentatious rip-offs as well as serpent oil, such as a dementia-reversing miracle therapy, a diabetes destroyer material as well as a life-saving cancer cells treatment that a Nazi drug store allegedly established at Hitlers command. Peppered in between these messages funded by third-party hucksters are main advertisements from Donald Trumps governmental reelection campaign.

For months, participants of the head of states internal circle consisting of Donald Trump Jr., Senate Majority Leader Mitch McConnell (R-Ky), previous House Speaker Newt Gingrich as well as also Trump himself have actually been releasing require contributions with the newsletter, which usually heads out 5 or even more times each day. Many receivers were most likely unintentionally subscribed; I Love My Freedom, the team that runs the eponymous newsletter, has actually obtained an expanding checklist of Americans call info with a concealed e-mail collecting system including an internet of pro-Trump Facebook web pages.

Right- wing political leaders, companies as well as media electrical outlets have a background of dealing with unethical entities behind the scenes to earn money as well as press their programs. The Trump campaigns service with I Love My Freedom is no exemption.

I Love My Freedom (e-mail information multiplied by HuffPost).

By layout, its e-mails seem theyre sent out straight from Trump as well as his allies, though theyre in fact dispersed by means of [emailprotected] At all-time low, they birth please notes noting they were spent for by either the National Republican Senatorial Committee, its House equivalent, the McConnell Senate Committee, or the Trump Make America Great Again Committee (which is collectively run by the Republican National Committee as well as Trumps reelection campaign).

Renting out accessibility to collected e-mail listings is a typical as well as very profitable method worked out by traditional as well as liberal teams alike, commonly for political fundraising objectives. But points obtain morally dirty when e-mail representatives do not veterinarian their enrollers which can lead to e-mail receivers being flooded with ripoffs as well as scams, like the counterfeit cancer cells treatment. In this instance, nonetheless, the genuine inquiry is whether Trumps group troubled to veterinarian I Love My Freedom.

The campaign did not react to HuffPosts ask for remark.

I Love My Freedom, which makes up the newsletter as well as a conservative blog site called Trending Politics, belongs to Making Web LLC, a rare advertising company thats signed up in Minnesota to a 51- year-old male called Allan G. Ferretti.

Through the newsletter alone, I Love My Freedom has actually enhanced a list of aggressive rip-offs consisting of some that misleadingly link Trump, in spite of its negotiations with his campaign. Hours prior to dispersing a fundraising e-mail from the McConnell Senate Committee this month, I Love My Freedom discharged off a funded message advertising a breakthrough stem cell therapy which it baselessly suggested Trump is getting.

This has got Liberals jumping out of their seats, the e-mail checks out. President Trump is in perfect health how is it that hes so seemingly immune to old age? Well in recent years, billionaires like President Trump have increasingly turned to the power of Stem Cells.

Titled Trump Health Bombshell, the e-mail web links to a rambling item pitch that promotes $67 containers of stem cell tablets as the Holy Grail of aging backwards. These tablets make cells inside your body become physically younger, it asserts, without supplying a shred of clinical proof. I Love My Freedom has likewise spammed its customers with enrollers get-rich-quick plans consisting of a secret IRS loophole, as well as has actually routed them to video clips recommending elders ought to exchange their recommended medicines for tricksters supplements also advising that they can pass away if they do not.

Recent newsletter versions have actually circulated actual phony information, as well, installing advertisements camouflaged as write-ups that connect to internet sites stealthily copying genuine media electrical outlets.

I Love My Freedom e-newsletters have actually included misleading advertisements resulting in phony information websites copying genuine electrical outlets..

One such advertisement includes the message Royal Family Mourns As Tragedy Is Confirmed, along with a picture of Meghan Markle, the Duchess ofSussex Clicking on it causes a web site imitating U.S.A. Today that goes crazy regarding a skin care line, which it incorrectly asserts Markle released. Another, birthing the heading [BREAKING NEWS] Prayers Go Out to Oprah Winfrey, web links to a fraudulent information website marketing a Brain Booster supplement, which it brazenly states is in charge of Winfreys occupation success.

In enhancement to Trump, his oldest kid, McConnell as well as Gingrich, I Love My Freedom has actually likewise sent fundraising e-mails in behalf of previous White House press assistant Sarah Huckabee Sanders, House Minority Leader Kevin McCarthy (R-Calif), House Republican Whip Steve Scalise (R-La), previous United Nations Ambassador Nikki Haley,Rep Elise Stefanik (R-N.Y.),Rep David Joyce (R-Ohio), previous White House Deputy Chief of Staff Karl Rove as well as National Republican Congressional Committee Chairman TomEmmer

All were spent for by the NRCC, NRSC, McConnell Senate Committee or the Trump Make America Great AgainCommittee Only the NRCC reacted to an ask for remark.

We rented this list to prospect new donors. We do our best to vet each vendor, but similar to renting a car, it is impossible to know or control what every other renter does with a list they too are renting, spokesperson Chris Pack informed HuffPost.

We will not be using this vendor going forward.

I Love My Freedom constructed its cash-cow e-mail realm by spending virtually $2 million right into Facebook advertisements, which attract individuals in with clickbait surveys or pledges of free MAGA equipment, as well as result in web pages advising them to send their e-mail addresses. This immediately indications them as much as obtain the newsletter, in addition to its numerous funded messages.

The team likewise earns money by marketing Trump- themed product such as Make Liberals Cry Again hats, as well as organizing third-party advertisements on Trending Politics which was seen a million times last month alone, according to electronic analytics device ComparableWeb

I Love My Freedom did not accept HuffPosts ask for a meeting.

I Love My Freedom makes use of clickbait Facebook advertisements to gather individualss e-mails, after that subscribes them to its newsletter.

Ferretti released ilovemyfreedom.org in addition to the Facebook web page Trump for President Fan Club (currently President Donald Trump Fan Club, which has 1.6 million fans) in the summertime of 2015, as reporter April Glaser reported last loss in a write-up regarding I Love My Freedoms viral development on Facebook.

Its among greater than a lots preferred web pages the team runs to run its countless Facebook advertisements, consisting of Donald Trump Is My President, Donald Trump 2020 Voters, President Trump Has My Vote, Donald Trumps Americans, Team Trump Fan Club, The President Trump Fan Club, We Need Trump 2020 as well as President Trumps Patriot Army.

These web pages create a stream of hyper-partisan memes as well as Trending Politics post to their target market of millions. Boosted by Facebooks formula, the advertisements which largely target elders are in some cases seen thousands of countless times each.

This looks like an operation thats got a very highly engaged audience that would be a prime target for a lot of conservative politicians to try to raise grassroots money from, stated Michael Beckel, research study supervisor at the political reform team Issue One.

When you run a pro-Trump Facebook team with greater than a million participants, that can make your [email] checklist an appealing possession.

Trumps campaign has actually currently gathered a citizen e-mail checklist thats so big it leases it out to outdoors celebrations. So why would certainly his group wish to fundraise with I Love My Freedoms checklist particularly provided the teams historical connections to grifters as well as scam artist?

Its type of striking that the Trump campaign is making a financial investment in [I Love My Freedoms] checklist, kept in mindBeckel But a t completion of the day, he stated, much more e-mails still means more potential voters or donors for them.

Calling all HuffPost superfans!

Sign up for subscription to come to be a starting participant as well as aid form HuffPosts following phase

Original post:
Donald Trump Is Using An Insanely Sketchy Newsletter To Find Campaign Donors - The Union Journal

While stem cell treatment is not a technique to eradicate or fix coronavirus completely, there is proof to help the idea that infected patients, under the treatment, might be more receptive to survive the disease.

That's because, stem cells oppose viral infection due to the presence of specific qualities known as interferon gamma invigorated qualities (ISGs). These are present in stem cells before their separation process happens. Thus, stem cells can be expected to survive even if they are transferred into a patient with confirmed infection of coronavirus, as per Vipul Jain, CEO, Advancells, a research firm focusing on therapeutic applications of regenerative medicine.

Mr Jain said, Even medical science has determined how influenza virus A/H5N1, with a history of causing intense lung injury, was destroyed by human mesenchymal stromal cells (MSCs) in a mouse. Going back to basics has only expanded the chances of positive outcome.''

Mesenchymal stromal cells (MSCs) are those stem cells which can separate into an assortment of cell types. There are several other properties of MSCs which make them suitable for clinical trials, such as they have ability to reduce inflammation thus regulating the immune system back to healthy and an extraordinary capacity to find the damaged tissues in human body. They can even speed up the recovery of those damaged tissues.

For instance, to achieve desired outcome, specialists have used enormous quantities of MSCs with one patient in Baoshan (Yunnan) who got 3 implantations of 50 million umbilical blood cord derived MSCs, while every Beijing patients got 1 mixture of 1 million cells for every kilogram of weight.

According to Advancells observations, MSCs can be acquired from fat, which implies that everybody can use his/her cells, abolishing any contamination or fatalities. In any case, extending them to the amount required for implantation, takes 2 to 3 weeks which is why it is valuable to cryo-conserve (process of preserving cells prone to damage) an individual reservoir of MSCs, that would permit to get to an early and progressively beneficial treatment.

It may be noted that, some 14 trials have been conducted using stem cells to treat coronavirus patients in China. They recommended stem cells may be the option to fix the extreme organ damage brought about by the virus.

MSCs can lessen the overproduction of immunity cells caused as a response to the virus and lower down the levels of inflammatory substances. Thus, bringing the weak framework and the whole body back to its ordinary state,'' Mr. Jain said.

What can be securely said at this stage following this spearheading study, as per Advancells, is that MSCs demonstrate extraordinary potential to turn into an important part of eradicating something so huge coronavirus itself.

Commenting on India scenario, he further said, Sadly, India is slow in terms of awareness, also it is tough to convince ICMR with innovative ideas. China had used it and all patients who have gone for stem cell therapy were recovered. Israel just announced they would start a stem cell pilot for treating coronavirus.

You have reached your limit for free articles this month.

Register to The Hindu for free and get unlimited access for 30 days.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Visit link:
Stem cells may give a respite to COVID-19 infected - The Hindu

NEW YORK, March 20, 2020 /PRNewswire/ --

Global Autologous Cell Therapy Market 2020-2024The analyst has been monitoring the global autologous cell therapy market 2020-2024 and it is poised to grow by USD 1.97 bn during 2020-2024, progressing at a CAGR of 22% during the forecast period. Our reports on global autologous cell therapy market 2020-2024 provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

Read the full report: https://www.reportlinker.com/p04941084/?utm_source=PRN

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing demand for effective drugs for cardiac and degenerative disorders. In addition, limitations in traditional organ transplantations fueling demand for stem cell therapies is anticipated to boost the growth of the global autologous cell therapy market 2020-2024 as well.

Market SegmentationThe global autologous cell therapy market 2020-2024 is segmented as below:Therapy: Autologous Stem Cell Therapy

Autologus Cellular Immunotherapies

Application: Oncology

Musculoskeletal Disorders

Dermatology

Geographic Segmentation: North America

APAC

Europe

South America

MEA

Key Trends for global autologous cell therapy market 2020-2024 growthThis study identifies limitations in traditional organ transplantations fueling demand for stem cell therapies as the prime reasons driving the global autologous cell therapy market 2020-2024 growth during the next few years.

Prominent vendors in global autologous cell therapy market 2020-2024We provide a detailed analysis of around 25 vendors operating in the global autologous cell therapy market 2020-2024, including some of the vendors such as Bayer AG, Brainstorm Cell Therapeutics Inc., Daiichi Sankyo Co. Ltd., FUJIFILM Holdings Corp., Holostem Terapie Avanzate Srl, Osiris Therapeutics Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Sumitomo Chemical Co. Ltd. and Vericel Corp. .The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Read the full report: https://www.reportlinker.com/p04941084/?utm_source=PRN

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

View original post here:
The Global Autologous Cell Therapy Market is expected to grow by USD 1.97 bn during 2020-2024, progressing at a CAGR of 22% during the forecast period...

Hair loss has long been a chief complaint among women, especially as they age. It affects some 30 million women in the United States alone, according to the Cleveland Clinic, and will significantly impact more than 50 percent of women during their lifetime. The most common cause is female-pattern hair loss (FPHL), also known as androgenetic alopecia. It's a chronic and progressive condition that has a genetic component, but it's also caused by factors related to the actions of hormonesovarian cysts, use of high androgen index birth control pills, pregnancy, and menopause, explains Ken L. Williams Jr., D.O., hair restoration specialist, surgeon, founder of Orange County Hair Restoration in Irvine, California.

Other medical conditions are also to blame for hair loss in women, including thyroid disorders, polycystic ovary syndrome, anemia, and chronic illnessand the use of certain medications, many of which treat these conditions, can also lead to hair loss in women. "Certain types of autoimmune disorders result in a slightly different and often less dramatic hair loss problem known as alopecia areata, an inflammatory condition that causes hair to come out in clumps or patches," says Dr. Williams Jr.

Luckily, we've come a long way in terms of treating hair loss. After all, 100 years ago, remedies involved things like snake oil and bat and chicken dung. "In more recent years, clinically tested topical and oral products, such as Minoxidil and Propecia, have become available, as well as procedures like PRP (platelet rich plasma therapy), and hair transplants," shares Anabel Kingsley, consultant trichologist and brand president for Philip Kingsley. She finds a holistic, personalized, multi-pronged approach to be the most effective way to treat any form of hair loss. "Since there is no 'one size fits all,' you want to optimize all possible factors that can affect the hair growth cycle, such as general health, nutrition, and stress levels, as well as the condition of your hair and scalp," she says.

At Philip Kingsley, she treats clients with their Trichotherapy Regime ($215, saksfifthavenue.com), which is specifically formulated for women with fine hair and reduced volume. "It tackles hair loss from all possible angles via the scalp with intensive daily Scalp Drops($89, neimanmarcus.com),a daily Stimulating Scalp Tonic ($28, net-a-porter.com), a thickening protein spray, and targeted masks to optimize the scalp environment," Kinglsey explains. "It also contains carefully formulated nutritional supplements to help give hair support from within."

Related: The Best Shampoos to Support Thinning Hair and Fight Female Hair Loss

Over-the-counter solutions won't work for every person suffering from hair loss, but there are a number of medical interventions that can stimulate hair growthanti-androgen medication, for example, is recommended for clients experiencing prolonged hair loss. "These medications help prevent further hair loss and encourage some hair regrowth from dormant hair follicles," says Dr. Williams Jr. There is also stem cell therapy, which has expanded greatly over the last few years in treating medical disease. "As opposed to embryonic cells, the initial stigma of using stem cells has decreased since the discovery of using bone marrow, fat cells, umbilical cord cells, and even skin cells to extract stem cells," he explains.

Surgery is also an option, and there are currently two primary surgical techniques or methods used in performing hair transplantation: Follicular Unit Transplantation (FUT) and Follicular Unit Extraction (FUE). "With the FUT technique, a section of scalp is excised with a scalpel, the scalp is brought together with sutures or staples and the hair follicles or hair grafts are inserted into tiny slits placed by the surgeon in the balding recipient area," Dr. Williams Jr. says. "The follicles with a single hair are placed in the front rows to define and create a natural hairline and the more dense, natural occurring follicular units are placed by hand in areas where hair density is needed the most."

FUE, a minimally invasive technique that is being hailed as the most significant improvement in hair surgery, uses a minimal depth scoring punch device to loosen the follicle from the surrounding tissues. "With the FUE procedure, a 0.9 or 1.0 millimeter punch minimal depth scoring excision is used in the skin around the upper part of the follicular unit (hair follicles)," he continues. "The hair follicle is then extracted directly from the scalp and manually placed into tiny slits in the balding area similar to the strip method."

There are still several hair restoration solutions left to be discoveredand experts believe most of us will see the concept of hair cloning come to fruition in their lifetime. "Hair cloning would in effect, disassemble a few hair follicles, multiply these cells in the laboratory and then reintroduce them into the scalp to both rejuvenate miniaturizing hair follicles and induce brand new hairs," Dr. Williams Jr. says. "Other groups have tried this but it has been found that when human follicle cells are cultured, they rapidly lose their functionality."

View original post here:
The Forefront of Treating Hair Loss in Women - Yahoo Lifestyle

GOLDEN, CO / ACCESSWIRE / March 18, 2020 / Vitro Diagnostics, Inc. (OTC PINK:VODG), dba Vitro Biopharma reports on its therapy for the Coronavirus (COVID-19) pandemic. Recent umbilical cord stem cell therapies in China to fight the Coronavirus are producing encouraging safety and efficacy results.

https://www.scmp.com/news/china/society/article/3053080/coronavirus-critically-ill-chinese-patient-saved-stem-cell

http://www.aginganddisease.org/article/0000/2152-5250/ad-0-0-216.shtml

Dr. Jim Musick, Ph.D., CEO said, "As the world struggles to deal with the COVID-19 pandemic, it is important to consider stem cell therapy to reduce death rates. This is supported by clinical studies and clinical trials are underway to substantiate safety and efficacy. Vitro Biopharma is ideally suited to provide high quality stem cells to US patients, produced under strict quality control in a cGMP, ISO9001 & ISO13485 Certified environment. Our umbilical cord AlloRx Stem Cells and stem cell growth media MSC-Gro have been used in the treatment of hundreds of patients without adverse events and show efficacy in treatment of COPD, osteoarthritis, multiple sclerosis and Alzheimer's disease.

Out of years of research, we developed our patent-pending and proprietary line of umbilical cord derived stem cells AlloRx Stem Cells now being used in offshore regenerative medicine clinical trials. Our stem cells are used in regenerative medicine clinical trials with our partner in the Cayman Islands http://www.DVCStem.com. We have a recently approved clinical trial using our AlloRx Stem Cells to treat musculoskeletal conditions at The Medical Pavilion of the Bahamas http://www.tmp-bahamas.com in Nassau.

Vitro Biopharma has a patent-pending, proprietary and scalable manufacturing platform to provide stem cell therapies to critically ill Coronavirus patients. Our stem cells have been shown to be safe in Phase I protocols as we also gain evidence of efficacy.

We are in contact with federal, state and local governments to inform them of our AlloRx Stem Cell therapy option for Coronavirus infections.. The pandemic deserves consideration of all therapeutic options and there is evidence that stem cell therapy reduces the death rate from Coronavirus COVID-19 infections. We believe that critically ill patients should have the right to try stem cell therapy in the United States."

Story continues

CONTACT:

Dr. James MusickChief Executive OfficerVitro Biopharma(303) 550-2778E-mail: jim@vitrobiopharma.com

Forward-Looking Statements

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company's auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements". Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Vitro Diagnostics, Inc.

View source version on accesswire.com: https://www.accesswire.com/581365/Stem-Cell-Therapy-for-the-Coronavirus-COVID-19-Pandemic

Read more:
Stem Cell Therapy for the Coronavirus COVID-19 Pandemic - Yahoo Finance

For their study, Terzic and colleagues analyzed the hearts of mice that received cardiopoietic stem cell therapy as well as those that did not. They used an algorithmic approach to map the proteins in the heart muscle, identifying 4,000 proteins. Ten percent of these were damaged during a heart attack.

The investigators found that the therapy either fully or partially reversed two-thirds of the changes caused by the event. And about 85% of cellular functional categories impacted by infarction responded positively to treatment, the authors wrote. They also noted that new blood vessels and heart tissue began to grow as a result of the intervention.

In the United States, someone has a heart attack every 40 seconds, according to the study, which kills this precious cardiac tissue and leads to a significantly weaker heart. Although cardiopoietic stem cells are still being investigated in advanced clinical trials in human patients, this most recent study is a big step in the right direction.

The current findings will enrich the base of knowledge pertinent to stem cell therapies and may have the potential to guide therapeutic regimens in the future," Terzic concluded.

The rest is here:
Stem cell therapy revives cardiac muscle damaged during heart attacks - Cardiovascular Business

Article In Brief

Mice with an open- and closed-traumatic brain injury were injected with immunomodulatory nanoparticles that reduced brain swelling and damage on MRI.

Investigators used a novel approach to prevent the swelling that can occur after traumatic brain injury (TBI) in a mouse model: they injected nanoparticles that trick white blood cells into going after them instead of rushing to the injured brain and causing an inflammatory and immune response.

Mice with TBI that were given three injections of the immunomodulatory nanoparticles beginning two to three hours after injury showed less brain swelling and damage on MRI as compared with mice with TBI that did not get the nanoparticles; the treated mice also performed better on functional tests.

The immunomodulatory nanoparticle treatment, if further proven in preclinical trials and human trials, would not undo damage from the initial injury to the brain. But it could help prevent the body from setting off a cascade of immune and inflammatory cells in reaction to the injury, which in turn can cause brain swelling and even more damage to brain tissue.

We certainly haven't gone and magically prevented that initial damage, said Jack Kessler, MD, professor of neurology at Northwestern University Feinberg School of Medicine and the senior author of the paper. What we can do is prevent the secondary damage, which is substantial.

Predicting which TBI patients will develop edema of the brain isn't easy, so having a preventive treatment like the nanoparticles that could be administered upfront could be life-altering, Dr. Kessler said.

He said some patients with head injuries come into the hospital walking and talking, but then their brain swells, and they die.

According to background in the study, published January 10 online in Annals of Neurology, each year more than 2.5 million people in the US have a traumatic brain TBI and more than five million Americans live with at least one sequela of TBI.

After the primary injury, there is substantial secondary injury attributable to infiltrating immune cells, cytokine release, reactive oxygen species, excitotoxicity, and other mechanisms, the study authors wrote. Despite many preclinical and clinical trials to limit such secondary damage, no successful therapies have emerged.

The nanoparticles tested in the mouse experiments are made of material used in biodegradable sutures. The paper specifically described the particles as highly negatively charged, 500 nm-diameter particles composed of the Food and Drug Administration (FDA)-approved biodegradable biopolymer carboxylated poly (lactic-co glycolic) acid.

The nanoparticles (IMPs), which seem like foreign invaders to the body's immune system, attract the attention of large white blood cells known as monocytes, which have been implicated in the secondary damage that occurs with TBI.

IMPs bind to the macrophage receptor with collagenous structure (MARCO) on monocytes and monocytes bound to IMPs no longer home to sites of inflammation but rather are sequestered in the spleen, where the cells die, the study authors wrote.

The mouse study involved two types of head injury. In some of the mice, the researchers performed a craniotomy to create a controlled cortical impact. Other mice received a closed head injury involving a direct blow to the head. Both types of injuries were meant to mimic what occurs in humans with TBI.

Injections of the nanoparticles were given two to three hours after the brain injury, and again at 24 hours and 48 hours post-injury. Control animals with similar brain injuries were given saline solution at the same time points.

Outcomes for the mice who received the nanoparticles were better by multiple measures, including MRI and a motor function test called the ladder rung walking test that is used in mouse experiments.

IMP administration resulted in remarkable preservation of both tissue and neurological function, in both models of head injury, the paper said. After acute treatment, there was a reduction in the number of immune cells infiltrating into the brain, mitigation of the inflammatory status of the infiltrating cells, improved electrophysiological visual function, improved long-term motor behavior, reduced edema formation as assessed by magnetic resonance imaging, and reduced lesion volumes on anatomic examination.

Dr. Kessler said that in the case of mice with an open head injury, the size of their brain lesion was 50 percent smaller in the treated animals compared with those that did not get the nanoparticles.

He said MRI showed significantly less brain swelling and less compression of the ventricles, both signs that secondary damage was minimized.

Dr. Kessler said that right now the only recourse for severe brain swelling is to do a craniotomy to relieve pressure in the skull.

He said one of the appeals of the nanoparticle treatment is that an emergency medical technician could do it in the field or the emergency room personnel could inject it.

But Dr. Kessler is also cautious about too many predications based on a pre-clinical study, saying he is fond of telling medical students that if I had a nickel for every mouse we cured, I'd be a rich man.

Sripadh Sharma, PhD, an MD-PhD student at Northwestern and the study's first author, said the nanoparticle therapy needs to be tested further in animal models before it could go into human testing. The researchers also want to learn more about how the nanoparticles bring about a reduced immune response in the body.

Dr. Sharma noted that while immune responses are a good thing in the face of injury or infection, sometimes nature doesn't always get it right, so too much of a good thing is a bad thing. And that can be the case with TBI.

He said it has been shown by another collaborator on the study, Stephen Miller, PhD, that when the scavenger receptors on the monocytes detect the light negative charge of the nanoparticles, the monocytes engulf and bind to the particles and apoptose in the spleen instead of going to the site of injury.

More studies need to be done to optimize what dose and what time these particles need to be given following a head injury, said Dr. Sharma.

Similar nanoparticle therapy is being tested for other medical conditions, including celiac disease and myocardial infarction, Dr. Kessler said.

Michael J. Schneck, MD, FAAN, professor of neurology (and neurosurgery) at Loyola University Chicago, said the study was well-designed and thorough, using two different head injury models and multiple outcome measures, including brain imaging, functional testing, and brain tissue analysis. Dr. Schneck said the paper made him wonder whether a similar approach using immune-modulating nanoparticles could reduce inflammatory-related damage following stroke and spinal cord injury.

Dr. Schneck said the concept of trying to dampen the immune response after TBI to prevent edema is not new, but the Northwestern researchers took the idea in a new direction. The nanoparticle therapy is particularly intriguing, he said, because it is fairly simple and involves the use of a material that is already approved by the US FDA, which could mean that it would take less time to move the therapy from the laboratory into clinical trials.

This is a very elegant study with interesting translational potential, he said. But it is a mouse model and its application to (human) TBI and other forms of central nervous system injury remains to be validated.

Jiangbing Zhou, PhD, associate professor of neurosurgery and biomedical engineering at Yale University, said that as someone who does research in the field of nanomedicine, he was surprised by the study's findings and wants to understand how this simple formulation particle could achieve this marked efficacy.

The study looks very exciting, but I want to know more about the mechanism, said Dr. Zhou, whose research focuses on developing translational nanomedicine, gene therapy, and stem cell therapy for neurological disorders including TBI.

He had these and other questions about the study: Why do the particles interact specifically with the inflammatory monocytes but not the others? How do the particles, which are made of safe biomaterials, efficiently kill the inflammatory monocytes in the spleen? What is happening and why?

Javier Crdenas, MD, director of the Barrow Concussion and Brain Injury Center at the Barrow Neurological Institute, said the study on the immune-modulating nanoparticle therapy for TBI was very promising, though he stressed that he is always cautiously optimistic when he sees a mouse study.

It is definitely a novel approach to addressing the secondary sequelae of brain injury and they might have something that minimizes that and hopefully improves outcomes, Dr. Crdenas said.

He said the study also raises some questions, including how the immune-modulating approach would fare in patients who have multiple injuries, not just to the head.

Dr. Crdenas said brain injuries often do not happen in isolation, with patients also having broken bones, lacerations, and other organ damage.

We don't know how this (nanoparticle treatment) would affect other organs, other immune responses elsewhere in the body, he said.

Dr. Crdenas said the field of TBI research has been disappointed before by studies of new therapies that looked promising in animal models and clinical testing but ultimately failed. He noted, for instance, that progesterone and hypothermia did not turn out to be good at preventing brain swelling.

We will wait and see, he said of the nanoparticles.

Drs. Sharma, Schneck, Zhou, and Crdenas had no disclosures.

More here:
Nanoparticle Therapy Might Help Reduce Brain Swelling in... : Neurology Today - LWW Journals

Canine Stem Cell Therapy Market Segmentation

The Canine Stem Cell Therapy Market is an intrinsic study of the current status of this business vertical and encompasses a brief synopsis about its segmentation. The report is inclusive of a nearly accurate prediction of the market scenario over the forecast period market size with respect to valuation as sales volume. The study lends focus to the top magnates comprising the competitive landscape of Canine Stem Cell Therapy Market, as well as the geographical areas where the industry extends its horizons, in magnanimous detail.

The market report, titled Canine Stem Cell TherapyMarket Research Report 2019 By Manufacturers, Product Type, Applications, Region and Forecast to 2029, recently added to the market research repository of details in-depth past and present analytical and statistical data about the Canine Stem Cell Therapy Market. The report describes the Canine Stem Cell Therapy Market in detail in terms of the economic and regulatory factors that are currently shaping the markets growth trajectory, the regional segmentation of the Canine Stem Cell Therapy Market, and an analysis of the markets downstream and upstream value and supply chains.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.xploremr.com/connectus/sample/2360

The report offers the market growth rate, size, and forecasts at the global level in addition as for the geographic areas: Latin America, Europe, Asia Pacific, North America, and Middle East & Africa. Also, it analyses, roadways and provides the global market size of the main players in each region. Moreover, the report provides knowledge of the leading market players within the Canine Stem Cell Therapy Market. The industry-changing factors for the market segments are explored in this report. This analysis report covers the growth factors of the worldwide market based on end-users.

In accordance with a competitive prospect, this Canine Stem Cell Therapyreport dispenses a broad array of features essential for measuring the current Canine Stem Cell Therapy Market performance along with technological advancements, business abstract, strengths and weaknesses of market position and hurdles crossed by the leading Canine Stem Cell Therapy Market players to gain leading position. Other aspects such as customer base, sales reach, local coverage, production price trends, and production cost layout are also analyzed to bestow accurate rivalry perspective.

Pivotal highlights of Canine Stem Cell Therapy Market:

Get Full Report Access athttps://www.xploremr.com/cart/2360/SL

The report covers exhaustive analysis on:

Regional analysis includes

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! https://www.xploremr.com/connectus/check-discount/2360

Benefits of Purchasing from XMR:

About Us

XploreMR is one of the worlds leading resellers of high-quality market research reports. We feature in-depth reports from some of the worlds most reputed market research companies and international organizations. We serve across a broad spectrum from Fortune 500 to small and medium businesses. Our clients trust us for our unwavering focus onquality and affordability. We believe high price should not be a bottleneck for organizations looking to gain access to quality information.

Contact us:

XploreMR111 North Market Street, Suite 300,San Jose, CA 95113, United StatesPh.No: +16692840108E-mail id-[emailprotected]Web-https://www.xploremr.com

Original post:
Canine Stem Cell Therapy Market Future Opportunities, Production/Demand Analysis & Outlook 2029 - Packaging News 24

Researchers are occupied with finding novel strategies to make human stem cells. This is to address the expanding interest for stem cell creation for potential examination in malady administration. This factor is absolutely anticipated that would quicken the improvement of regenerative pharmaceutical, along these lines driving mechanical development. Also, cellular treatments are perceived as the following real progressions in changing social insurance. Firms are extending their cellular therapy portfolio, understanding the future capability of this field in the treatment of Parkinsons ailment, type 1 diabetes, spinal string damage, Alzheimers sickness, and others.

One of the essential variables driving this present Stem Cell Therapy market development is the restrictions in customary organ transplantations. The developing worries with organ transplantations have driven the interest for stem cell therapy items. Traditional organ gift is related with disease hazard, immunosuppression hazard, and dismissal. Additionally, the interest for organs is expanding, and the doctors very subject to organ benefactors. To beat these issues scientists are presently investigating approaches to distinguish the use of stem cell treatments in different transplants. For example, pluripotent stem cells offer a conceivably boundless wellspring of human cells, which can determine the majority of the cells in the body. Besides, the join dismissal can be diminished with the stem cells, as these are developed utilizing a similar individual cells. These points of interest in the transplantations of organs will bring about the development of the worldwide stem cell therapy market.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787

Another key variables boosting the development of this market is the constraints of customary organ transplantation, for example, the danger of disease, dismissal, and immunosuppression hazard. Another disadvantage of ordinary organ transplantation is the fact that specialists need to rely upon organ contributors totally. Every one of these problems can be killed, by the utilization of stem cell therapy. The other factor which is helping the development in this market is the developing pipeline and advancement of medications for rising applications. Expanded research thinks about meaning to extend the extent of stem cell will likewise fuel the development of the market. Researchers are continually occupied with endeavoring to discover novel strategies for making human stem cells because of the developing interest for stem cell creation to be utilized for malady administration.

The worldwide market for stem cell therapy can be fragmented into North America, Europe, Latin America, Asia Pacific, the Middle East and Africa. North America rose as the main territorial market, activated by the rising rate of government help and interminable wellbeing conditions. Europe additionally shows huge development potential, as the advantages of this therapy are progressively recognized.

Asia Pacific is known for most extreme development, on account of the monstrous patient pool, main part of interests in stem cell therapy ventures, and the expanding acknowledgment of development openings in nations, for example, Japan, China, and India by the main market players.

The worldwide stem cell therapy market is in an early stage with the nearness of couple of universal merchants. With changing directions regarding transplantations in different created and creating nations, various new players are relied upon to enter the market space. Additionally, the developing pipeline and advancement of medications for rising applications will build the opposition among merchants amid the conjecture time frame.

Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1787

Other conspicuous merchants in the stem cell therapy market incorporate VistaGen Therapeutics, AbbVie, Anterogen, Astellas Pharma, Beike Biotechnology, Cellular Dynamics International (a backup of Fujifilm), Cellular Biomedicine Group, Opsis Therapeutics, Mesoblast, Laboratorios Salvat, TWO CELLS, Pharmicell, Ivy Institute of Stem Cells, Pluristem Therapeutics, U.S. Stem Cell, Taiwan Bio Therapeutics, ReNeuron, Translational Biosciences, Nuo Therapeutics, BIOTIME, Promethera Biosciences.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Link:
Stem Cell Therapy Market: Using Stem Cell Therapy to Accelerate Cardiovascular Healing - BioSpace

AmnioBoost has potential for use in the treatment of ARDS, which is the principal cause of death in COVID-19 infection.1 Mortality in COVID-19 infected patients with the inflammatory lung condition (ARDS) is reported to approach 50%, and is associated with older age, co-morbidities such as diabetes, higher disease severity, and elevated markers of inflammation.1 Current therapeutic interventions do not appear to improve in-hospital survival.1

AmnioBoost is believed to have immunomodulatory properties to counteract the inflammatory processes that are implicated in several diseases by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.

Major anti-inflammatory cytokines found in AmnioBoost include: interleukin (IL)-1beta, IL-1ra, TNF-alpha, IL-6, IL-8, IL-16, CCL2, CXCL7, MIF, and GRO a/b/g. Specific cytokine receptors for IL-1, and tumor necrosis factor-alpha, function as proinflammatory cytokine inhibitors.

This is supported by recently published results from an investigator-initiated clinical study conducted in China which reported that allogeneic mesenchymal stem cells (MSCs) cured or significantly improved functional outcomes in all seven treated patients with severe COVID-19 pneumonia.2

AmnioBoost

AmnioBoost was originally developed for chronic adult inflammatory conditions such as osteoarthritis, but has found multiple uses in the treatment of bone and cartilage repair, as well as soft tissue repair. It is an investigational therapy comprising concentrated allogeneic MSCs and cytokines derived from amniotic fluid.

The amniotic fluid is donated from non-related, healthy mothers and recovered by caesarian section; the baby is not harmed in any way. Additionally, AmnioBoost has been injected in over 1,000 patients with no adverse events, and appears to be well tolerated.

References

1. Liu Y et al. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. Medrxiv 2020; https://doi.org/10.1101/2020.02.17.20024166 2. Leng Z, et al. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia[J]. Aging and Disease, 10.14336/AD.2020.0228

About Lattice Biologics Ltd.:

Lattice Biologics is traded on the TSX-V under the symbol: LBL. The Company is an emerging leader in the field of cellular therapies and tissue engineering, with a focus on dental indications.

Lattice Biologics develops and manufactures biologic products to domestic and international markets. The Companys products are used in a variety of surgical applications.

Lattice Biologics maintains its headquarters, laboratory and manufacturing facilities in Belgrade, Montana as well as offices in Phoenix, Arizona. The facility includes ISO Class 1000 clean rooms, and specialized equipment capable of crafting traditional allografts and precision specialty allografts for various clinical applications. The Lattice Biologics team includes highly trained tissue bank specialists, surgical technicians, certified sterile processing and distribution technicians, and CNC operators who maintain the highest standards of aseptic technique throughout each step of the manufacturing process. From donor acceptance to the final packaging and distribution of finished allografts, Lattice is committed to maintaining the highest standards of allograft quality, innovation, and customer satisfaction.

Lattice Biologics maintains all necessary licensures to process and sell its tissue engineered products within the U.S. and internationally. This includes Certificates to Foreign Governments from the U.S. Food and Drug Administration (FDA) and registrations for multiple countries, which allow the export of bone, tendon, meniscus, ligament, soft tissue, and cartilage products outside of the U.S.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement on Forward-Looking Information:

Certain information contained in this news release constitutes forward-looking statements within the meaning of the safe harbour provisions of Canadian securities laws. All statements herein, other than statements of historical fact, are to be considered forward looking. Generally, forward-looking information can be identified by the use of forward-looking terminology such as planned, potential, future, expected, could, possible, goal, intends, will or similar expressions. Forward-looking statements in this news release include, without limitation: information pertaining to the Companys strategy, plans, or future financial performance, such as statements with respect to the Transaction, and other statements that express managements expectations or estimates of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Lattice to be materially different from those expressed or implied by such forward-looking statements.

Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by management as of the date such statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies. The factors and assumptions that could prove to be incorrect, include, but are not limited to: that market prices will be consistent with expectations, the continued availability of capital and financing, and that general economic, market and business conditions will be consistent with expectations. The forward-looking statements are not guarantees of future performance. We disclaim any obligation to update or revise any forward-looking statements, except as required by law. Readers are cautioned not to put undue reliance on these forward-looking statements.

United States Advisory: The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the U.S. Securities Act) unless an exemption from the registration requirements of the U.S. Securities Act is available. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.

Subscribe to Lattice News Updates Follow us on Twitter: @LatticeBio

View source version on businesswire.com: https://www.businesswire.com/news/home/20200313005049/en/

Link:
Lattice Biologics to Evaluate Anti-Inflammatory Stem Cell Therapy Treatment of COVID-19 Lung Disease - BioSpace

Researchers report that a patient who underwent stem-cell transplantation and a chemotherapy drug regimen has been cured of HIV.

An HIV patient to undergo stem cell transplantation from donors with a HIV-resistant gene no longer suffers from the condition, according to a new study. Researchers reveal that there was no active viral infection in the patients blood 30 months after they stopped anti-retroviral therapy, making him the second person cured of HIV.

However, they report that although there was no active viral infection in the patients body, remnants of integrated HIV-1 DNA remained in tissue samples, which were also found in the first patient to be cured of HIV. The authors suggest that these can be regarded as so-called fossils, as they are unlikely to be capable of reproducing the virus.

We propose that these results represent the second ever case of a patient to be cured of HIV. Our findings show that the success of stem cell transplantation as a cure for HIV, first reported nine years ago in the Berlin patient, can be replicated, said lead author on the study, Professor Ravindra Kumar Gupta at the University of Cambridge, UK.

The London and Berlin patient are examples of using the CCR5 gene in curative therapies outside of gene editing

He emphasised that as a high-risk treatment, this therapy is unlikely to be offered widely to patients with HIV who are on successful antiretroviral treatment.

In 2011, a patient based in Berlin (the Berlin patient) was the first HIV patient to be reportedly cured of the virus three and half years after undergoing similar treatment. This therapy included total body irradiation, two rounds of stem cell transplant from a donor who carried a CCR532/32 gene, which is resistant to HIV and finally a chemotherapy drug regimen. The transplant aimed to make the virus unable to replicate in the patients body, whilst the body irradiation and chemotherapy targeted any residual HIV virus.

The patient reported in this study (the London patient), underwent one stem-cell transplantation and a reduced-intensity chemotherapy drug regimen, without whole body irradiation. In 2019, it was reported that his HIV was in remission and the new study provides follow-up viral load blood test results at 30-months, as well as a modelling analysis to predict the chances of viral re-emergence.

Ultrasensitive viral load sampling from the London patients cerebrospinal fluid, intestinal tissue or lymphoid tissue was taken at 29 months after interruption of antiretroviral therapy (ART) and viral load sampling of his blood at 30 months. At 29 months, CD4 cell count (indicators of immune system health and stem cell transplantation success) was measured and analysed to identify the extent to which the patients immune cells have been replaced by those derived from the transplant.

The results showed no active viral infection was detected in samples of the patients blood at 30 months or in his cerebrospinal fluid, semen, intestinal tissue and lymphoid tissue 29 months after stopping ART.The patient also had a healthy CD4 cell count, suggesting he recovered well from the transplant, with his CD4 cells replaced by cells derived from the HIV-resistant transplanted stem cells. Furthermore, 99 percent of his immune cells were derived from the donors stem cells, indicating the stem-cell transplant had been successful.

The authors highlight that their case study of the London patient represents a step towards a less intensive treatment approach. They suggest that the long-term remission of HIV can be achieved using reduced intensity drug regimens, with one stem cell transplant (rather than two) and without total body irradiation.

However, being only the second reported patient to undergo this experimental treatment successfully, the authors note that that the London patient will need continued, but much less frequent, monitoring for re-emergence of the virus.

Speculating on what their results might mean for future developments of HIV cures that utilise the CCR5 gene, co-author on the study, Dr Dimitra Peppa at the University of Oxford, UK, said: Gene editing using the CCR5 has received a lot of attention recently. The London and Berlin patient are examples of using the CCR5 gene in curative therapies outside of gene editing. There are still many ethical and technical barriers eg, gene editing, efficiency and robust safety data to overcome before any approach using CCR5 gene editing can be considered as a scalable cure strategy for HIV.

The study was published in The Lancet HIV.

HIV

Follow this link:
Second patient cured of HIV using stem cell therapy - European Pharmaceutical Review